Status: Recruiting
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
This clinical trial is evaluating a drug called AC676 in participants with Relapsed/Refractory B-cell Malignancies. The main goals of the study are to: * Identify the recommended dose of AC676 that can be given safely to participants * Evaluate the safety profile of AC676 * Evaluate the pharmacokinetics of AC676 * Evaluate the effectiveness of AC676
Participants needed: 60
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Accutar Biotechnology IncUpdated: Oct 2, 2025Locations: 9
Eligibility criteria
Adult male and female patients, at least 18 years-of-age at the time of signatur... [+2]
Small molecule anti-cancer drugs within 5 half-lives or 2 days (whichever is lon... [+8]